Effects of citrate acid concentrate (Citrasate®) on heparin N requirements and hemodialysis adequacy: A multicenter, prospective noninferiority trial

Blood Purification

Volumn 33, Issue 1-3, 2012, Pages 199-204

  Sands, Jeffrey J ^a   Kotanko, Peter ^b,c   Segal, Jonathan H ^d   Ho, Chiang Hong ^a   Usvat, Len ^b   Young, Amy ^e   Carter, Mary ^b   Sergeyeva, Olga ^a,b   Korth, Lisa ^e   Maunsell, Eileen ^a   Zhu, Yueping ^a   Krishnan, Mahesh ^e   Diaz Buxo, Jose A ^a  

^a Fresenius Medical Care North America   (United States)

^b RENAL RESEARCH INSTITUTE   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e DAVITA CLINICAL RESEARCH   (United States)

Author keywords

Citric acid dialysate; Dialysate; Hemodialysis; Heparin N

Indexed keywords

ACETIC ACID; ANTITHROMBOCYTIC AGENT; BICARBONATE; CITRASATE; CITRIC ACID; CITRIC ACID DIALYSATE; HEPARIN; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTERIOVENOUS FISTULA; ARTERY GRAFT; ARTIFICIAL KIDNEY; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; DIALYSATE; DRUG EFFECT; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HEMODIALYSIS; HEMOSTASIS; HUMAN; HYPOCALCEMIA; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; ORAL PARESTHESIA; PRIORITY JOURNAL; THROMBOSIS; TREMOR; UNSPECIFIED SIDE EFFECT;

AGED; ANTICOAGULANTS; CITRIC ACID; DIALYSIS SOLUTIONS; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84862781639     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000334157     Document Type: Conference Paper

References (14)

1. 510(K) Summaries or 510(K) Statements for Final Decisions Rendered during the Period June 1, 2000 through June 30, 2000; 510(k) No. K000792. http://www.accessdata.fda. gov/cdrh-docs/pdf/k000792.pdf.
2. Ahmad S, Callan R, Cole JJ, Blagg CR: Dialy-sate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis 2000; 35: 493-499.
3. Bauer E, Derfler K, Joukhadar C, Druml W: Citrate kinetics in patients receiving long-term hemodialysis t herapy. A m J K idney Dis 2005; 46:903-907.
4. O'Shea SI, Ortel TL, Kovalik EC: Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003; 16:61-67.
5. Kossmann RJ, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol 2009; 4:1459-1464.
6. Gabutti L, Lucchini B, Marone C, Alberio L, Burnier M: Citrate-vs. acetate-based dialy-sate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes. BMC Nephrol 2009; 10:7.
7. Tu A, Ahmad S: Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients. Dial Transplant 2000; 29: 620-626.
8. Kossmann, R, Callan R, Ahmed S: Fifty-five percent heparin reduction is safe with citrate dialysate in chronic dialysis patients (abstract). J Am Soc Nephrol 2006; 17:109-110.
9. Dittrich M, Callan R, Ahmad S: High citrate dialysate is safe and permits heparin free chronic hemodialysis (abstract). J Am Soc Nephrol 2008; 19: 461.
10. Ahmad S, Callan R, Cole JJ, Blagg CR: Increased dialyzer reuse with citrate bicarbonate dialysate. Hemodial Int 2005; 9: 264-267.
11. Valentine KA, Hull RD: Therapeutic use of heparin and low molecular weight heparin; in Leung LK, Landaw SA (eds): UpToDate for Medicine v 17.2. www.uptodate.com, 2009.
12. Lohr JW, Schwab SJ: Minimizing hemor-rhagic complications in dialysis patients. J Am Soc Nephrol 1991; 2: 961-975.
13. Kishimoto TK, Viswanathan K, Ganguly T, et al: Contaminated heparin associated with adverse clinical events and activation of the contact system. N Eng l J Med 2008; 358: 2457-2467.
14. Golper TA, Ward RA: Dialysate- Ho-Hum! Clin J Am Soc Nephrol 2009; 4:1403-1404.